Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 4/20 | 0.56 |
| ▸ | SLC9A1 | P19634 | 12/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763934 | 0.91 | SLC9A1 (0.54) | RBP4SLC9A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1763563 | 0.90 | SLC9A1 (0.51) | RBP4SLC9A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1763651 | 0.88 | SLC9A1 (0.46) | RBP4SLC9A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1762989 | 0.88 | SLC9A1 (0.49) | RBP4SLC9A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1763910 | 0.86 | SLC9A1 (0.47) | RBP4SLC9A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1763801 | 0.86 | SLC9A1 (0.55) | RBP4SLC9A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1764257 | 0.86 | SLC9A1 (0.47) | RBP4SLC9A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1763560 | 0.86 | SLC9A1 (0.55) | RBP4SLC9A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1763596 | 0.84 | SLC9A1 (0.57) | RBP4SLC9A1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1763378 | 0.84 | RBP4 (0.63) | RBP4SLC9A1CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | RBP4 4521/4885SLC9A1 2/4885CYP2C9 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.